are due to the N-terminal fatty acyl-Dab 1 . Polymyxin B (2-10) and colistin (2) (3) (4) (5) (6) (7) (8) (9) (10) are cyclic nonapeptides obtained respectively from polymyxin B and colistin by enzymic removal of fatty acyl-Dab-OH with ficin 13) or papain. 14) The toxicity of the nonapeptides is known to be markedly low in comparisons with the parent compounds, polymyxin B and colistin; however, both nonapeptides are very weak bactericidals despite the fact that they retain considerable binding activity to LPS. 15) Therefore, the development of nonapeptide analogs with increased antimicrobial activity and/or higher LPS binding activity is of interest.
Previously, we reported a strategy for chemically converting natural polymyxin B and colistin to their N-terminal analogs.
2) The side chains of Dab residues in the natural peptides were first protected by trifluoroacetyl (Tfa) groups; the key step of the conversion strategy was the treatment of the N g -protected natural peptides with aqueous methanesulfonic acid (MSA) [16] [17] [18] [19] [20] in order to cleave N a -alkanoyl-Dab(Tfa)-OH. Tetrakis(N g -Tfa)-polymyxin B (2-10) and tetrakis(N gTfa)-colistin (2) (3) (4) (5) (6) (7) (8) (9) (10) , which have N a -free and N g -protected amino functions, were useful starting materials for the semisynthesis of their N-terminal derivatives. However, the yields of tetrakis(N g -Tfa)-polymyxin B (2-10) and tetrakis(N g -Tfa)-colistin (2-10) were only 8-11%. In this study, we investigated the trichloroethoxycarbonyl (Troc) group as an alternative acid-resistant N g -protecting group for the Dab residues of polymyxin B and colistin, and sixteen N a -acylated nonapeptide analogs (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) were synthesized by an improved semi-synthetic route in order to develop nonapeptide analogs with potent antimicrobial and LPS binding activities.
Results and Discussion
Semi-synthesis As reported previously, 2) the preparation of N a -free and N g -protected nonapeptides from N g -protected cyclic decapeptides was the key step for the semi-synthesis of N-terminal nonapeptide analogs of polymyxin B and colistin. In the present study, Troc was examined as an acid-resistant protecting group for the Dab side chains of polymyxin B and colistin. Pentakis(N g -Troc)-polymyxin B (1) and pentakis(N g -Troc)-colistin (2) were prepared almost quantitatively by treating commercially available polymyxin B or colistin with Troc-Cl and triethylamine (TEA) in 90% dimethylformamide (DMF). To avoid derivatizing Thr side chains at positions 2 and 10 with Troc, aqueous DMF was used as the solvent. The resulting pentakis(N g -Troc)-polymyxin B (1) and pentakis(N g -Troc)-colistin (2) were dissolved in trifluoroacetic acid (TFA) : MSA : DMF : H 2 O (10 : 30 : 55 : 5), and the solution was allowed to react at 40°C for 48 h to remove fatty acyl-Dab(Troc)-OH. After cleavage, the product was treated with diluted ammonia to reverse the N-O migration products, as reported previously. 2) Following purification by RP-HPLC, the new key compounds, tetrakis(N g -Troc)-polymyxin B (2-10) (3) and tetrakis(N g -Troc)-colistin (2-10) (4), were obtained in 18.9% and 15.2% yield, respectively (Fig. 1 ). Higher yields of these key compounds compared to that of their Tfa derivatives may be attributable not only to changing the protecting group from Tfa to Troc, but also to changes in the reaction conditions, since using a very low content of H 2 O in the MSA-TFA-DMF mixture should result in higher selectivity during the hydrolysis reaction as reported in the selective chemical removal of acyl amino acids from the N-terminally acylated peptides such as pGlu-peptides and Myr-Gly-peptides. 2, [16] [17] [18] [19] The removal of fatty acylDab(Troc)-OH from 1 and 2 by the cleavage of Dab(Troc)-Thr bond at the positions 1-2 was considered to be facilitated through N-O migration, 2) however, the cleavage of another bond at positions 9-10 seemed to be unavoidable, resulting in the still unsatisfactory yields of 3 and 4.
The N-terminal acylation of tetrakis(N g -Troc)-polymyxin B (2-10) (3) and tetrakis(N g -Troc)-colistin (2-10) (4) with fatty acids was achieved using HATU as the coupling reagent. Eight fatty acids bearing aliphatic or aromatic ring Fig. 2 . Synthesis of Polymyxin B (2-10) and Colistin (2-10) Derivatives structures were examined in this study (Fig. 2) . The resulting N a -fatty acylated tetrakis(N g -Troc)-polymyxin B (2-10) (5a-12a) and N a -fatty acylated tetrakis(N g -Troc)-colistin (2-10) (13a-20a) were treated with Zn in AcOH to remove the Troc groups. The products were purified first by RP-HPLC and then by gel-filtration, using 5 mmol/l hydrochloric acid as the eluent, to yield fatty acyl-nonapeptides as their tetrahydrochlorides. The structures of the synthetic polymyxin B (2-10) analogs (5-12) and colistin (2-10) analogs (13) (14) (15) (16) (17) (18) (19) (20) , shown in Fig. 2 , were confirmed by FAB-MS. The purity of these synthetic peptides was demonstrated by analytical HPLC as representatively shown in Fig. 3 for analog 8 (the purity 97%), as well as HP-TLC. Thus, starting from the new key compounds 3 and 4 highly pure fatty acyl-nonapeptides were obtained using a single coupling reaction, followed by deprotection. Recently, a strategy for the synthesis of tetra-tert-butyloxycarbonyl (Boc)-protected polymyxin B nonapeptide was reported by O'Dowd et al. 21) employing non-protected polymyxin B (2-10) as the starting material, and the selective tetra-Boc-protection of the Dab side chain amino groups to produce N a -free tetrakis(N g -Boc)-polymyxin (2-10) was described.
Concerning the bactericidal activity of synthetic polymyxin peptides, there were the discrepancies among published reports. Octanoyl-colistin (2-10) synthesized in our previous study showed the potent activity against Escherichia coli (E. coli) with the MIC value of 1 nmol/l, 2) however, the same compound reported by Chihara was 10-20 times less active, which was prepared by the reaction of octanoyl chloride directly with colistin nonapeptide bearing five free amino functions. 22) This product was contaminated with 20% of N g -octanoyl-colistin nonapeptide(s), which were estimated by quantitative analysis of N a -DNP-Thr and N g -DNP-Dab in the dinitrophenylated octanoyl-colistin nonapeptide preparation.
22) The activity of our synthetic myristoyl-colistin (2-10) also differed from that reported 30 years ago. 23 ) Thus, we demonstrated in the previous paper 2) that the N-terminal structure-activity relationship of polymyxin B and colistin should be re-examined using highly pure synthetic peptides as these descrepancies are believed to be due to differences in the purities of the synthetic peptides. In the present study, the chemical conversion route described above was applied to search for potent bioactive acyl-nonapeptide analogs bearing aliphatic or aromatic ring structure in the acyl group (Fig.  2) .
Antimicrobial Activity of Synthetic Peptides Introduction of fatty acids bearing aliphatic or aromatic ring structures to the nonapeptides polymyxin B (2-10) and colistin (2-10) greatly increased their bactericidal activity. Three polymyxin B (2-10) analogs, acylated with 1-adamantaneacetyl-(5), 4-biphenylacetyl-(7), and cyclohexylbutanoyl- (8) , showed potent antimicrobial activities equal to that of polymyxin B. 2-Anthracenecarbonyl-(6), 1-pyrenebutanoyl- (9) , and cyclododecanecarbonyl-(11) analogs exhibited slightly reduced antimicrobial activity, equal to that of octanoyl-polymyxin B (2-10) 24) and octanoyl-colistin (2-10), 2) which were recently reported to have MIC values of 1.0-4.0 nmol/ml against E. coli and Salmonella Typhimurium (S. Typhimurium), respectively. trans-4-Propylcyclohexanecarbonyl-polymyxin B (2-10) (10) and 2-cyclopentylphenylacetyl-polymyxin B (2-10) (12) showed reduced activities, with MIC values of 4 and 8 nmol/ml, respectively (Table 1) , similar to that reported by Tsubery for Fmocpolymyxin B (2-10), which has a MIC value of 8 mg/ml.
25) It seems likely that the antimicrobial activities of polymyxin B (2-10) analogs bearing various fatty acyl groups are slightly higher against E. coli and S. Typhimurium than those of the corresponding colistin (2-10) analogs. The activities of various colistin (2-10) analogs varied in an approximately similar manner as the corresponding polymyxin B (2-10) analogs. These results suggest that, for antimicrobial activity, D-Phe at position 6 is superior to D-Leu in this family of peptides.
It is well known that the nonapeptides polymyxin B (2-10) and colistin (2-10) have almost no antimicrobial activity. 13, 14, 24) However, introduction of octanoyl to the N a -amino function of nonapeptides greatly increases their activity. 2, 24) In this study it was found that cyclohexylbutanoyl-polymyxin B (2-10) (8) showed two-fold higher antimicrobial activity against E. coli compared with polymyxin B, and its activity against S. Typhimurium and Pseudomonas aeruginosa (P. aeruginosa) was equal to that of polymyxin B. Analog 8 is the most potent synthetic polymyxin B nonapeptide analog reported to date. The cyclohexyl ring structure located at the terminus (the 4-position of butanoyl) in 8 seems to cause favorable interactions with the bacterial cell membrane. However, a cyclohexyl ring located at the carbonyl of the acyl group seems to be unfavorable, since trans-4-propylcyclohexylcarbonyl-polymyxin B (2-10) (10) shows low activity. In this regard, biphenylacetyl-analogs (7, 15) show high activity, while 2-cyclopentylphenylacetyl-analogs (12, 20) with a branched bulky structure close to the N-terminus of Thr 2 show low activity. The sensitivity of E. coli and S. Typhimurium to polymyxin B (2-10) and colistin (2-10) analogs varied according to the N-terminal fatty acyl group on the nonapeptide, but the sensitivity of P. aeruginosa did not. Previously we reported that acetyl-polymyxin B (2-10) and acetyl-colistin (2-10) retained the potent bactericidal activity only against P. aeruginosa, but not against E. coli and S. Typhimurium.
2) Taking into account the previous results, it is possible to say that the peptide portions of polymyxin B and colistin contributes greater to destroy the cell membrane of P. aeruginosa than fatty acyl portion, and it seems likely that the constitution of the P. aeruginosa cell membrane differs from that of other Gram-negative bacteria. analogs (6, 14) and 1-pyrenebutanoyl-analogs (9, 17) were not examined because these compounds disturbed fluorescence measurements of the dansyl group. Although none of the synthetic nonapeptides examined showed LPS binding activity comperable to polymyxin B, 4-biphenylacetylpolymyxin B (2-10) (7), cyclohexylbutanoyl-polymyxin B (2-10) (8), and cyclododecanecarbonyl-polymyxin B (2-10) (11) showed LPS binding activities close to that observed for octanoyl-polymyxin B (2-10). 24) 1-Adamantaneacetylpolymyxin B (2-10) (5) and propylcyclohexanecarbonylpolymyxin B (2-10) (10) showed low LPS binding activity. Analog 5, as well as 7 and 8, were potent bactericidals, com- perable to polymyxin B (Table 1) . Thus, the antimicrobial and LPS binding activities of these compounds are not parallel. These results suggest that 1-adamantaneacetyl-polymyxin B (2-10) (5) is a potent bactericidal agent that exhibits moderate activity for neutralizing the endotoxin. Previously we reported that myristoyl-polymyxin B (2-10) and myristoylcolistin (2-10) show potent LPS binding activity but have lower antimicrobial activity than polymyxin B, with a MIC value of 4.0 nmol/ml against E. coli.
LPS Binding Activity
2) Thus, myristoylpolymyxin B (2-10) may have potent neutralizing activity against endotoxin while retaining moderate antimicrobial activity. 2-Cyclopentylphenylacetyl-polymyxin B (2-10) (12) and cyclopentylphenylacetyl-colistin (2-10) (20) , which have a bulky structure close to the N-terminus of Thr 2 , showed very low LPS binding activity and 8-16 fold lower antimicrobial activity. Colistin (2-10) analogs less effectively displaced dansylated polymyxin B 3 bound to LPS than polymyxin B (2-10) analogs, suggesting that D-Phe at position 6 is superior to D-Leu for LPS binding activity in this family of peptides.
In conclusion, the synthetic strategy for converting natural polymyxin B and colistin to their N-terminal analogs was improved twice in the present study with regard to the yields of the key intermediates, tetrakis(Troc)-polymyxin B (2-10) and tetrakis(Troc)-colistin (2-10). Acylation of these key intermediates with various fatty acids, followed by deprotection with Zn-AcOH to remove the Troc protecting group, provided various nonapeptide analogs in good yields. The present study demonstrates that fatty acylated polymyxin B (2-10) analogs bearing aliphatic or aromatic ring structures are synthetic antibiotics whose characteristics depend on the specific fatty acyl group in the compound. Among sixteen synthetic analogs, cyclohexylbutanoyl-polymyxin B (2-10) (8) was found to be as potent a bactericidal agent as polymyxin B against E. coli, S. Typhimurium and P. aeruginosa, but its binding activity was slightly lower than polymyxin B or myristoyl-polymyxin B (2-10). 1-Adamantaneacetyl-polymyxin B (2-10) (5) showed lower LPS binding activity than polymyxin B, but the analog 5 was a potent bactericidal.
Experimental
General Fast-atom bombardment mass spectra (FAB-MS) were obtained on a JMS-DX300 mass spectrometer (JEOL Ltd., Japan). The optical rotations of the peptides were measured using a DIP-370 digital polarimeter (JASCO Co., Ltd., Japan). HPLC was performed on a system comprised of a PX-8010 gradient controller (Tosoh, Japan), two CCPD pumps (Tosoh), a Rheodyne 7125 injector (Rheodyne Inc., U.S.A.) or an AS-8020 automatic sample injector (Tosoh), a UV 8000 detector (Tosoh), and an 805 data station (Waters). HP-TLC was performed on precoated silica-gel plates (Kieselgel 60, E. Merck, Germany). -trichloroethoxycarbonyl) -polymyxin B (1) Polymyxin B sulfate (Wako, Japan; 868 mg, 0.60 mmol, calculated as Polymyxin B 1 sulfate) was suspended in 95% DMF (80 ml) containing TEA (834 ml, 6.0 mmol), and Troc-Cl (822 mg, 6.0 mmol) was added while the mixture was cooled with ice. The mixture was allowed to react for 24 h at room temperature while the pH was maintained at 7.8 with TEA. The product was solidified by addition of cold H 2 O (320 ml), collected by filtration, dried, and then reprecipitated from MeOH-AcOEt-ether-petr. ether. Yield: 1019 mg (81.7%, calculated as pentakis(N g -trichloroethoxycarbonyl)-polymyxin B 1 ). The crude product was used for the next reaction without further purification. A small amount of material from the main peak of this product was isolated by RP-HPLC on a YMC Pack D-ODS-5ST column (150ϫ20 mm). 1 (93.58 mg, 45 mmol) was dissolved in trifluoroacetic acid (TFA) (3 ml) cooled in ice, then a mixture of methanesulfonic acid (MSA) : dimethylformamide (DMF) : water (30 : 55 : 5) (27 ml) was added and the reaction mix was stirred at 40°C for 48 h. The mixture was added directly to a Wakogel 50C18 column (5ϫ6 cm), which was washed with H 2 O (400 ml) to remove MSA. Reaction products were eluted with 75% aqueous dioxane (350 ml). The eluates were combined, cooled in an ice bath, and a dilute ammonia solution (0.5 mol/l, 35 ml) was then added. The mixture was stirred for 30 min while cooled with ice, then the solvent was removed under vacuum. The residue was re-dissolved in 90% aqueous dioxane (50 ml), and then lyophilized. The obtained powder was dissolved in 90% dioxane, and then purified by RP-HPLC on a YMC Pack D-ODS-5ST column (150ϫ20 mm) using a linear gradient (30 min) from 45.6 to 56.05% CH 3 CN in 0.1% TFA at a flow rate of 5 ml/min. The eluate was evaporated and lyophilized, then the obtained product was re-lyophilized from 75% dioxane (50 ml) containing 1 mol/l HCl (0.1 ml). 
1-Adamantaneacetyl-polymyxin B (2-10) Tetrahydrochloride (5)
To a solution of 3 (25.5 mg, 15 mmol) and N-methylmorpholine (NMM) (3.06 ml, 30 mmol) in DMF (600 ml), a mixture of 1-adamantaneacetic acid (11.66 mg, 60 mmol) and HATU (22.8 mg, 60 mmol) in DMF (300 ml) was added while the mixture was cooled with ice. The mixture was stirred at room temperature for 3 h and its pH was maintained at 7.8 with NMM. The mixture was applied to a Toyopearl HW-40 column (100ϫ2 cm) and eluted with DMF : water (9 : 1). The eluate fractions containing the main product were combined and evaporated in vacuo. The residue was lyophilized from dioxane (3 ml) to give 1-adamantaneacetyl-tetrakis(N g -trichloroethoxycarbonyl)-polymyxin B (2-10) (5a .28 mg)-AcOH (5 ml) at 40°C overnight. After filtration, the product was purified by RP-HPLC on a YMC Pack D-ODS-5ST column (20ϫ150 mm) using linear gradient elution (30 min) from 25.65 to 30.4% CH 3 CN in 0.1% TFA at a flow rate of 5 ml/min. The eluate fractions containing the main peak product were collected, evaporated and lyophilized. The product was applied to a Toyopearl HW-40 column (100ϫ2 cm) and eluted with 25% CH 3 CN in 5 mM HCl. The collected eluate fractions containing the main product were combined, evaporated and lyophilized. Purified 5 was relyophilized from 75% dioxane. Yield (5) 
2-Anthracenecarbonyl-polymyxin B (2-10) Tetrahydrochloride (6)
To a solution of 3 (25.5 mg, 15 mmol) and NMM (3.06 ml, 30 mmol) in DMF (600 ml), a mixture of 2-anthracenecarboxylic acid (13.33 mg, 60 mmol) and HATU (22.8 mg, 60 mmol) in DMF (300 ml) was added. The mixture was stirred at room temperature for 3 h and treated in the same manner as described for 5a to give 2-anthracenecarbonyl-tetrakis(N g -trichloroethoxycarbonyl)-polymyxin B (2-10) (6a 
4-Biphenylacetyl-polymyxin B (2-10) Tetrahydrochloride (7)
To a solution of 3 (25.5 mg, 15 mmol) and NMM (3.06 ml, 30 mmol) in DMF (600 ml), a mixture of 4-biphenylacetic acid (12.73 mg, 60 mmol) and HATU (22.8 mg, 60 mmol) in DMF (300 ml) was added while the reaction mix was cooled with ice. The mixture was stirred at room temperature for 5 h and treated in the same manner as described for 5a to give 4-biphenylacetyltetrakis(N g -trichloroethoxycarbonyl)-polymyxin B (2-10) (7a (18. 58 mg, 10 mmol) was treated with Zn (4 mmol, 261.52 mg)-AcOH (2.5 ml) at 40°C for 3 h. After filtration, the product was purified in the same manner as described for 5. Yield (7) 
Cyclohexylbutanoyl-polymyxin B (2-10) Tetrahydrochloride (8)
To a solution of 3 (25.5 mg, 15 mmol) and NMM (3.06 ml, 30 mmol) in DMF (600 ml), a mixture of cyclohexylbutyric acid (10.22 mg, 60 mmol) and HATU (22.8 mg, 60 mmol) in DMF (300 ml) was added while the reaction mix was cooled with ice. The mixture was stirred at room temperature for 2 h and treated in the same manner as described for 5a to give cyclohexylbutanoyl-tetrakis(N g -trichloroethoxycarbonyl)-polymyxin B (2-10) (8a 
1-Pyrenebutanoyl-polymyxin B (2-10) Tetrahydrochloride (9)
To a solution of 3 (25.5 mg, 15 mmol) and NMM (3.06 ml, 30 mmol) in DMF (600 ml), a mixture of 1-pyrenebutyric acid (17.3 mg, 60 mmol) and O- (7- azabenzotriazol-1-yl)-1,1,3,3 -tetramethyluronium hexafluorophosphate (HATU) (22.8 mg, 60 mmol) in DMF (300 ml) was added while the mixture was cooled with ice. The mixture was stirred at room temperature for 2 h and treated in the same manner as described for 5a to give 1-pyrenebutanoyl-tetrakis(N g -trichloroethoxycarbonyl)-polymyxin B (2-10) (9a (19. 34 mg, 10 mmol) was treated with Zn (4 mmol, 261.52 mg)-AcOH (2.5 ml) at 40°C for 20 h. After filtration, the product was purified in the same manner as described for 5. Yield (9) 
Cyclododecanecarbonyl-polymyxin B (2-10) Tetrahydrochloride (11)
To a solution of 3 (25.5 mg, 15 mmol) and NMM (3.06 ml, 30 mmol) in DMF (600 ml), a mixture of cyclododecanecarboxylic acid (12.74 mg, 60 mmol) and HATU (22.8 mg, 60 mmol) in DMF (300 ml) was added while the mixture was cooled with ice. The mixture was stirred at room temperature for 1 h and treated in the same manner as described for 5a to give cyclododecanecarbonyl-tetrakis(N g -trichloroethoxycarbonyl)-polymyxin B (2-10) (11a To a solution of 3 (25.5 mg, 15 mmol) and NMM (3.06 ml, 30 mmol) in DMF (600 ml), a mixture of cyclopentylphenylacetic acid (12.26 mg, 60 mmol) and HATU (22.8 mg, 60 mmol) in DMF (300 ml) was added while the mixture was cooled with ice. The mixture was stirred at room temperature for 1 h and treated in the same manner as described for 5a to give cyclopentylphenylacetyl-tetrakis(N g -trichloroethoxycarbonyl)-polymyxin B (2-10) (12a 
2-Anthracenecarbonyl-colistin (2-10) Tetrahydrochloride (14)
To the solution of 4 (25.0 mg, 15 mmol) and NMM (3.06 ml, 30 mmol) in DMF (600 ml), a mixture of 2-anthracenecarboxylic acid (13.33 mg, 60 mmol) and HATU (22.8 mg, 60 mmol) in DMF (300 ml) was added while the mixture was cooled with ice. The mixture was stirred at room temperature for 1 h and treated in the same manner as described for 5a to give 2-anthracenecarbonyl-tetrakis(N g -trichloroethoxycarbonyl)-colistin (2-10) (14a 
4-Biphenylacetyl-colistin (2-10) Tetrahydrochloride (15)
To the solution of 4 (25.0 mg, 15 mmol) and NMM (3.06 ml, 30 mmol) in DMF (600 ml), a mixture of 4-biphenylacetic acid (12.73 mg, 60 mmol) and HATU (22.8 mg, 60 mmol) in DMF (300 ml) was added while the mixture was cooled with ice. The mixture was stirred at room temperature for 2 h and treated in the same manner as described for 5a to give 4-biphenylacetyltetrakis(N g -trichloroethoxycarbonyl)-colistin (2-10) (15a and NMM (3.06 ml, 30 mmol) in DMF (600 ml), a mixture of cyclohexylbutyric acid (10.22 mg, 60 mmol) and HATU (22.8 mg, 60 mmol) in DMF (300 ml) was added while the mixture was cooled with ice. The mixture was stirred at room temperature for 1 h and treated in the same manner as described for 5a to give cyclohexylbutanoyl-tetrakis(N g -trichloroethoxycarbonyl)-colistin (2-10) (16a To the solution of 4 (25.0 mg, 15 mmol) and NMM (3.06 ml, 30 mmol) in DMF (600 ml), a mixture of 1-pyrenebutyric acid (17.3 mg, 60 mmol) and HATU (22.8 mg, 60 mmol) in DMF (300 ml) was added while the mixture was cooled with ice. The mixture was stirred at room temperature for 1 h and treated in the same manner as described for 5a to give 1-pyrenebutanoyltetrakis(N g -trichloroethoxycarbonyl)-colistin (2-10) (17a 
Cyclododecanecarbonyl-colistin (2-10) Tetrahydrochloride (19)
To the solution of 4 (25.0 mg, 15 mmol) and NMM (3.06 ml, 30 mmol) in DMF (600 ml), a mixture of cyclododecanecarboxylic acid (12.74 mg, 60 mmol) and HATU (22.8 mg, 60 mmol) in DMF (300 ml) was added while the mixture was cooled with ice. The mixture was stirred at room temperature for 1 h and treated in the same manner as described for 5a to give cyclododecanecarbonyl-tetrakis(N g -trichloroethoxycarbonyl)-colistin (2-10) (19a (20) To the solution of 4 (25.0 mg, 15 mmol) and NMM (3.06 ml, 30 mmol) in DMF (600 ml), a mixture of cyclopentylphenylacetic acid (12.26 mg, 60 mmol) and HATU (22.8 mg, 60 mmol) in DMF (300 ml) was added while the mixture was cooled with ice. The mixture was stirred at room temperature for 4 h and treated in the same manner as described for 5a to give cyclopentylphenylacetyl-tetrakis(N g -trichloroethoxycarbonyl)-colistin (2-10) (20a 
Antimicrobial Activities of Synthetic Polymyxin B and Colistin Analogs
The antimicrobial activities of the synthetic peptides were estimated using the standard micro plate dilution method reported previously. 24) LPS Binding Activity LPS binding activity was examined according to the method reported by Moore. 26) A solution of [Dab(Dansyl-Gly) 1 ]-polymyxin B 3 (4 nmol) and 30 mg of LPS (E. coli, serotype005:B5, Sigma Chemical Co.) in 5 mM N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid (HEPES) buffer (pH 7.2, 1 ml) was incubated in a quartz cuvette at 30°C for 1 h, then a peptide solution (1 mm/ml) (4 ml each) was added in the same manner as reported previously. 24) The fluorescence spectra were measured using a fluorescence spectrophotometer F-4500 (Hitachi Instrument Co., Tokyo, Japan) at an excitation wavelength of 330 nm and an emission wavelength of 490 nm.
